Overview
CRAI market data
Price History
CRAI price chart
Valuation & Profitability
- P/E (TTM)
- 21.34 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $8.16 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.68 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 1.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 6.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $132.17 – $227.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.1B · P/B 6.54 · P/S 1.32.
Company News
8-K filing — CRA INTERNATIONAL, INC. (CRAI)SEC EDGAR · Aug 6, 2026, 12:15 PM
CRA Intl Raises FY2026 Sales Guidance from $785.000M-$805.000M to $805.000M-$820.000M vs $801.210M EstBenzinga · Aug 6, 2026, 12:14 PM
CRA Intl Q2 Adj. EPS $2.16 Beats $2.15 Estimate, Sales $210.815M Beat $198.903M EstimateBenzinga · Aug 6, 2026, 12:11 PM
BriaCell Therapeutics Engages Charles River Associates, Kaleio To Explore Commercial Strategy, Market Access Evaluation Of Bria-IMTBenzinga · Jul 7, 2026, 11:40 AM